Related Experiment Video
Updated: Jul 9, 2025

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
Published on: July 27, 2021
The capsid revolution
Ian A Taylor1, Ariberto Fassati2,3
1M acromolecular Structure Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
None:
Lenacapavir, targeting the human immunodeficiency virus type-1 (HIV-1) capsid, is the first-in-class antiretroviral drug recently approved for clinical use. The development of Lenacapavir is attributed to the remarkable progress in our understanding of the capsid protein made during the last few years. Considered little more than a component of the virus shell to be shed early during infection, the capsid has been found to be a key player in the HIV-1 life cycle by interacting with multiple host factors, entering the nucleus, and directing integration. Here, we describe the key advances that led to this 'capsid revolution'.
More Related Videos
12:57Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity
Published on: November 16, 2017
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
Related Concept Videos
Viral Structure
Retrovirus Life Cycles
Lytic Cycle of Bacteriophages
Retroviruses
Viral Mutations
Viral Recombination